CytoReason
Machine Learning for Data-driven Target Discovery and Drug Development
Company Overview
Snapshot
Founded in September 2016 by Prof. Shai, Elina Starosvetsky, Shai Shen-Orr, and David Harel, CytoReason operates with 51–200 employees. The company has raised over $132 million across 6 funding rounds from 6 investors. In July 2024, CytoReason secured a C Round of funding, with participation from Nvidia and Pfizer.
Business overview
CytoReason is a technology company that develops a computational model of the human body to simulate human disease at a cellular level. Its core technology leverages a proprietary database and an AI-led platform to enable pharmaceutical and biotechnology companies to make data-driven decisions. The company's solutions aim to minimize the need for animal trials, make human trials more focused and accurate, identify new opportunities, shorten trial phases, reduce development costs, and increase the likelihood of drug approval. CytoReason operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Medical Decision Support, serving pharmaceutical companies, healthcare providers, and laboratories globally, including in the United States, Japan, and Europe.
Strategic signal
In January 2026, CytoReason unveiled LINA, an AI agent accelerated by Nvidia, designed to support pharmaceutical research and development, built on computational disease models. This launch signifies CytoReason's continued innovation in AI-powered drug discovery and its strategic collaboration with a major technology player like Nvidia, indicating a strong push towards advanced computational solutions in the pharma R&D landscape.
Company Intelligence Q&A
- What was the most recent funding event for CytoReason?
- In July 2024, CytoReason secured a C Round of funding. Investors included Nvidia and Pfizer.
- What is CytoReason's collaboration with Sanofi?
- In January 2026, CytoReason announced the expansion of its collaboration with Sanofi to advance AI-driven drug discovery. This followed an earlier extension in January 2023 focusing on bowel disease drug discovery, and an initial collaboration in June 2021 to understand disease mechanisms using AI technology.
- What new AI agent did CytoReason unveil?
- In January 2026, CytoReason unveiled LINA, an AI agent accelerated by Nvidia, designed to support pharmaceutical research and development and built on computational disease models.
- What is CytoReason's relationship with Pfizer?
- In February 2022, Pfizer extended its cooperation deal with CytoReason for AI drug development. This built on a prior collaboration agreement signed in January 2018 to utilize CytoReason's machine learning model of the immune system for drug discovery.
- Has CytoReason expanded its market reach in Asia?
- In April 2022, CytoReason expanded its reach in Asia by forging a commercial alliance with Helixrus to leverage machine learning in drug development for Korean drugmakers. Additionally, in September 2021, CytoReason entered the Japanese market through a partnership with SPI.